Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report

Abstract

Abstract Coronavirus disease‐19 (COVID‐19) vaccines are massively administered globally and some adverse events, such as myocarditis, are being reported. Most of the reported cases of post‐vaccination myocarditis have occurred following mRNA vaccinations. However, there have also been recent reports of myocarditis following adenovirus vector vaccinations. We present a case of a 32‐year‐old female patient who developed myocarditis following the administration of the first dose of the AstraZeneca vaccine. The patient developed inappropriate exertional tachycardia and exertional dyspnea from Day 3 and was diagnosed with myocarditis by subsequent echocardiography about 3 months later. We are unable to confirm a direct association between myocarditis and AstraZeneca vaccination. However, we would like to increase awareness regarding the possibility of developing myocarditis following AstraZeneca vaccination.

Keywords

• AstraZeneca‐associated myocarditis
• COVID‐19 vaccination‐associated myocarditis
• mRNA COVID‐19 vaccines
• myocarditis
• viral vector vaccines